A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Active, not recruiting · NCT05918133 · Registry updated 2025-03-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC | Active, not recruiting | Phase 1 / Phase 2 | 2025-03-11 | NCT05918133 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Biotheus Inc. | 10 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Cancer Hospital of Harbin Medical University | Harbin | China | 4 |
| Fudan University Shanghai Cancer Center | Shanghai | China | 85 |
| Jiangsu Province Hospital | Nanjing | China | 37 |
| Nanchang Third Hospital | Nanchang | China | 2 |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing | China | 38 |
| The first ward of breast Surgery, Shandong Cancer Hospital | Jinan | China | 1 |
| Tian Jin Medicial University Cancer Institute&Hospital | Tianjin | China | 2 |
| Yibin Second People's Hospital | Yibin | China | 5 |